Cyrus Bio technology can speed new drug discovery
SEATTLE, WA December 29, 2017 — Cyrus Biotechnology, a biotechnology software company offering first-in-class tools for advanced protein modeling and discovery in drug development, announced today that it will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Lucas Nivon, CEO, will present at the Biotech Showcase™ as follows:
Date: Tuesday, January 9th, 2018
Time: 2:00PM PST
Room: Franciscan D (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Cyrus offers Bench®, a Software-as-a-Service platform for protein structure prediction, biologics discovery, alternative structure modeling, protein stabilization, engineering and design, along with custom software development and experienced scientific support services in computational protein engineering.
Bench® is based on two decades of work in computational biophysics and the first software algorithms to design new proteins in a computer. It has been designed for a wider range of users than previous academic-based software. Cyrus is rapidly acquiring customers ranging from Fortune 500 Pharma (including eight of the top 20 Pharma firms), chemical and consumer products firms to privately-held biotech and synthetic biology firms.
Bench® is a graphical, cloud-enabled version of the Rosetta protein modeling toolkit. Data generated from Rosetta technology can be used in the design of new potential therapeutics, such as a therapeutic protein of Tocagen’s Toca 511 and PVP Biologics’ KumaMax, an oral enzyme. Cyrus is funded by leading investors in both Tech and Biotech sectors, led by Trinity Ventures with Orbimed, SpringRock, W Fund and others.
“We are very excited to be presenting at Biotech Showcase™,” said Cyrus CEO Dr. Lucas Nivon. “Year after year, our participation in the J.P. Morgan Annual Healthcare Conference has been fruitful and productive for the organizations we have established partnerships with. Our Bench® technology broadens access to the most advanced biocomputational methods, giving more scientists the means to speed their research and save costs. The result is more effective drugs getting to patients sooner.”
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Cyrus Biotechnology will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others…
NOTICE: The information contained in this document is dated as of December 29, 2017. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact Lucas Nivon